

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

SHEEP LIVER PHOSPHOFRUCTOKINASE:
A COMPARISON OF THE PRIMARY STRUCTURE WITH THOSE OF OTHER
MAMMALIAN ISOZYMES

A Thesis presented in partial fulfilment of the
requirements for the degree of Doctor of Philosophy
in Biochemistry at
MASSEY UNIVERSITY

KAY JENICE RUTHERFURD

1988

ABSTRACT

Phosphofructokinase (PFK) is the key regulatory enzyme of glycolysis, catalysing the synthesis of fructose 1,6-bisphosphate from fructose 6-phosphate and ATP.

Several PFK isozymes have been identified from different tissues, including muscle, liver and platelet. Each isozyme is under the control of a different structural locus; in humans the muscle isozyme is carried on chromosome 1, liver on chromosome 21, and platelet on chromosome 10.

The tetramer of PFK is the lowest active form, and there are both species and tissue differences in the composition of the tetramer. Some, such as human muscle PFK consist of four identical subunits (M_4), whereas others, such as human erythrocyte PFK comprise a five membered isozyme system, made up of both muscle and liver subunits.

The activity of PFK is modulated by a variety of effectors such as; ATP, fructose 6-phosphate, ADP, AMP and fructose 2,6-bisphosphate, as well as covalent modification, and hormonal regulation. Each PFK isozyme exhibits its own characteristic kinetic properties in response to changes in effector concentrations. This project aims to compare the primary structures of two PFK isozymes; liver and muscle, from a single species (sheep), in order to explain their different kinetic properties in terms of differences in their primary structures.

A purification procedure for sheep liver PFK was developed, and a 48% yield was obtained, with a final specific activity of 100Units/mg of protein.

Sodium dodecyl sulphate-gel electrophoresis indicated a protomer molecular weight of 84 000 for sheep heart muscle PFK, and 81 000 for sheep liver PFK, indicating that liver PFK is approximately 30 residues shorter than the muscle enzyme.

The comparison of the amino acid compositions showed a significantly lower arginine and lysine content in liver PFK compared to muscle PFK. There was also a lower threonine content in liver PFK, accompanied by an increase in the number of serine residues, compared to muscle PFK. So overall, the number of residues with

hydroxy-alkyl sidechains remained the same. The tyrosine content of liver PFK was also higher than that of muscle PFK.

The comparison of HPLC and FPLC peptide maps of liver and muscle PFK provided by digestion with CNBr and trypsin, showed a number of interesting differences between the two isozymes. Generally, the CNBr peptides of liver PFK appeared to be smaller than those of muscle PFK, while the radioactively labelled cysteine containing peptides from the tryptic digest of muscle PFK, were more hydrophobic than those from liver PFK.

Sequence information was obtained from purified peptides produced by digestion of liver PFK with CNBr, trypsin, and trypsin following maleylation of the sheep liver PFK with maleic anhydride to block the lysine residues. 87% of the amino acid sequence of sheep liver PFK was determined, and aligned with the sequences from rabbit muscle and sheep heart PFK. Approximately 70% sequence identity was observed between the liver and muscle isozymes, particularly in the regions where contacts to substrates and effectors are thought to be made. There are two regions exhibiting major sequence changes between the muscle and liver isozymes, both are thought to lie on the exterior of the molecule, and therefore would not disrupt the tertiary structure. One of these regions however, is thought to contain the ATP inhibitory site; and the large variation in sequence at this site may explain the greater susceptibility of the liver enzyme to ATP inhibition. Other, more subtle changes in the sequence may account for the additional differences in the kinetic properties displayed by muscle and liver PFK.

ACKNOWLEDGEMENTS

I wish to thank my supervisors Dr C.H. Moore and Dr G.G. Midwinter for their invaluable advise, encouragement and assistance throughout the course of this study.

Thanks go also to Mr J.R. Reid for assistance with the amino acid analyses and running of the gas-phase sequencer, as well as Dr B.F. Anderson and Dr E.N. Baker for assistance with using the computer program FRODO and interpretation of some of the amino acid differences between the PFK isozymes.

I would also like to thank my husband Shane for his assistance in the preparation of this manuscript.

LIST OF ABBREVIATIONS

ADP	adenosine 5'-diphosphate
Am Bic	ammonium bicarbonate
AMP	adenosine 5'-monophosphate
ATP	adenosine 5'-triphosphate
β ME	β -mercaptoethanol
<u>Bs</u>	<u>Bacillus stearothermophilus</u>
BSA	bovine serum albumin
Ca ²⁺ -CaM	Ca ²⁺ -calmodulin complex
CaM	calmodulin
cAMP	cyclic-AMP
DNA	deoxyribonucleic acid
DTNB	5,5'-dithiobis-2-nitrobenzoic acid
DTT	dithiothreitol
<u>Ec</u>	<u>E. coli</u>
EDTA	ethylenediamine tetraacetic acid
F6P	fructose 6-phosphate
F16BP	fructose 1,6-bisphosphate

F26BP	fructose 2,6-bisphosphate
FBPase	fructose bisphosphatase
F16BPase	fructose 1,6-bisphosphatase
F26BPase	fructose 2,6-bisphosphatase
FDNB	1-fluoro-2,4-dinitrobenzene
FPLC	fast protein liquid chromatography
α -GPD	α -glycerophosphate dehydrogenase
G1P	glucose 1-phosphate
G6P	glucose 6-phosphate
G16BP	glucose 1,6-bisphosphate
HPLC	high performance liquid chromatography
MLCK	myosin light chain kinase
NADH	nicotinamide adenine dinucleotide, reduced form
PEG	polyethylene glycol-6000
PEP	phosphoenolpyruvate
PFK	phosphofructokinase
PFK-2	phosphofructokinase-2
Pi	inorganic phosphate
PMSF	phenylmethanesulphonyl fluoride

POPOP	1,4-bis[2(5-phenyloxazolyl)]benzene
PPO	2,5-diphenyloxazole
RM	rabbit muscle
SDS	sodium dodecyl sulphate
SH	sheep heart
SL	sheep liver
SDS-PAGE	sodium dodecyl sulphate-polyacrylamide gel electrophoresis
TCA	tricarboxylic acid
TEMED	N,N,N',N'-tetramethylethylenediamine
Tes	N-tris[hydroxymethyl]methyl-2-aminoethanesulphonic acid
TPCK	L-1-tosylamide-2-phenylethyl chloromethyl ketone
TPI	triose phosphate isomerase
Tris	tris (hydroxymethyl) aminomethane

The single letter amino acid code is used in accordance with the IUPAC recommendations.

TABLE OF CONTENTS

	<u>page</u>
ABSTRACT	ii
ACKNOWLEDGEMENTS	iv
LIST OF ABBREVIATIONS	v
TABLE OF CONTENTS	viii
LIST OF FIGURES	xv
LIST OF TABLES	
CHAPTER 1	
INTRODUCTION	1
1.1 General Background	1
1.2 Structural Aspects of Prokaryote and Eukaryote Phosphofructokinases	2
1.3 Phosphofructokinase Isozymes In Mammals	3
1.3.1 Tissue Distribution of Phosphofructokinase Isozymes	3
1.3.2 Developmental Changes	5
1.3.3 Separation of Phosphofructokinase Isozymes	6
1.3.4 Immunology of Phosphofructokinase Isozymes	6
1.3.4.1 Cross-Reactivity With Homotetramers	7
1.3.4.2 Cross-Reactivity With Heterotetramers	7
1.3.5 Structural Properties of Phosphofructokinase Isozymes	8
1.3.5.1 Subunit Molecular Weight	8
1.3.5.2 Aggregation State	8
1.3.6 Physical Properties of Mammalian Phosphofructokinase	11
1.3.7 Stability of Phosphofructokinase	11

1.4	Kinetic Properties of Muscle and Liver	
	Phosphofructokinase	12
1.4.1	Effects of ATP on Phosphofructokinase	12
	1.4.1.1 Effects of pH on ATP Inhibition	13
	1.4.1.2 Effect of F6P Concentration on ATP Inhibition	13
1.4.2	Effects of Adenine Nucleotides on Phosphofructokinase Activity	16
1.4.3	Effects of Fructose 1,6-Bisphosphate on Phosphofructokinase Activity	16
1.4.4	Activation of Phosphofructokinase By NH_4^+ and K^+	18
1.4.5	Inhibitors of Phosphofructokinase Activity	18
	1.4.5.1 Tricarboxylic Acid Cycle Intermediates	18
	1.4.5.2 Phosphate Esters	21
1.4.6	Fructose 2,6-Bisphosphate	23
	1.4.6.1 Effect of Fructose 2,6-Bisphosphate on Phosphofructokinase Activity	24
	1.4.6.2 Effects of Fasting on Fructose 2,6-Bisphosphate Levels	25
	1.4.6.3 Changes in Phosphofructokinase Activity in Response to Glucagon Administration	26
	1.4.6.4 Changes in Fructose 2,6-Bisphosphate Concentration in Response to Glucagon and Glucose Administration	26
	1.4.6.5 Effect of Fructose 2,6-Bisphosphate on Fructose 1,6-Bisphosphatase Activity	28
	1.4.6.6 Control of Glycolysis and Gluconeogenesis By Fructose 2,6-Bisphosphate	28
1.4.7	Covalent Modification of Phosphofructokinase By Phosphorylation	29
	1.4.7.1 Extent of Phosphorylation of Phosphofructokinase	29
	1.4.7.2 The Effects of Phosphorylation on Phosphofructokinase	31
	1.4.7.3 Site of Phosphorylation	33

	1.4.7.4	Factors Affecting Phosphorylation	34
	1.4.7.4.1	Effects of Glucagon and Glucose on the Phosphorylation of Phosphofructokinase	34
	1.4.7.5	Effect of Phosphorylation <u>In Vivo</u>	35
	1.4.7.6	Significance of Phosphorylation	35
	1.4.7.7	Phosphorylation and Actin	36
	1.4.8	Interaction of Calmodulin With Phosphofructokinase	37
	1.4.9	Effect of Hormones on Phosphofructokinase	40
	1.4.10	Phosphofructokinase Association With Structural Elements of the Cell	41
1.5		pH and Protonation	42
	1.5.1	Mechanism for the Inactivation of Phosphofructokinase By Decreasing pH	43
1.6		Glycolysis and Gluconeogenesis	44
1.7		Regulation of PFK Under Physiological Conditions	45
	1.7.1	Regulation of Muscle Phosphofructokinase Under Physiological Conditions	45
	1.7.2	Regulation of Liver Phosphofructokinase Under Physiological Conditions	46
1.8		Role of Specific Residues in Enzymic Activity	47
	1.8.1	Thiol Groups	47
	1.8.2	Identification of Reactive Cysteine Residues	50
	1.8.3	Reactive Methionine Residues	51
	1.8.4	Reactive Histidine Residues	52
1.9		Metabolite Binding Studies	52
1.10		The Evolution of Proteins	56
	1.10.1	Evolution of Glycolysis and Phosphofructokinase	58
1.11		Aims of This Project	59
CHAPTER 2		MATERIALS	61
CHAPTER 3		METHODS, RESULTS AND DISCUSSION OF THE PURIFICATION OF SHEEP HEART AND SHEEP LIVER PFK	63

3.1	Development of a Purification Procedure for Sheep Liver Phosphofructokinase	63
3.1.1	Homogenization Buffer Trial	63
	3.1.1.1 Procedure for the Homogenization Buffer Trial	66
3.1.2	Homogenization Experiment	68
3.1.3	Determination of the Effect of Fructose 2,6-Bisphosphate on the Thermal Stability of Liver Phosphofructokinase	68
	3.1.3.1 Method, and Results for the Fructose 2,6-Bisphosphate Heat Stabilization Trial	70
	3.1.3.2 Double Heat Step Trial	72
3.1.4	Ammonium Sulphate Precipitation Trial	72
3.1.5	Polyethylene Glycol Precipitation Trial	74
3.2	Purification of Sheep Liver Phosphofructokinase	77
3.3	Phosphofructokinase Enzyme Assays	80
3.4	Determination of Protein Levels	83
3.5	Preparation of the Cibacron Blue Column	83
3.6	Results and Discussion of the Purification of Sheep Liver Phosphofructokinase	83
	3.6.1 DEAE-Cellulose Chromatography of Sheep Liver Phosphofructokinase	83
	3.6.2 Cibacron Blue Chromatography of Sheep Liver Phosphofructokinase	85
	3.6.3 Summary of the Purification of Sheep Liver Phosphofructokinase	85
3.7	Purification of Sheep Heart Phosphofructokinase	90
3.8	Results and Discussion of the Sheep Heart Phosphofructokinase Purification	91
CHAPTER 4	METHODS	94
4.1	SDS-Polyacrylamide Gel Electrophoresis	94
	4.1.1 Preparation of Samples for SDS-Polyacrylamide Gel Electrophoresis	94
4.2	Carboxymethylation	95
4.3	Amino Acid Analysis	95

4.4	Tryptic Digestion of PFK	95
4.5	CNBr Digestion of PFK	96
4.6	Peptide Mapping of Sheep Heart and Liver PFK	96
4.6.1	Mapping of Tryptic Peptides Using HPLC	96
4.6.2	Mapping of CNBr Peptides Using HPLC	97
4.6.3	Mapping of CNBr Peptides Using FPLC	97
4.7	Determination of Radioactivity	98
4.8	Preparation of PFK Peptides for Sequencing	98
4.8.1	CNBr Peptides	98
4.8.2	Tryptic Peptides	100
4.8.3	Maleyl-Tryptic Peptides of Liver PFK	100
4.8.3.1	Maleylation of Liver PFK	100
4.8.3.2	Tryptic digest of Maleylated Liver PFK	100
4.8.3.3	Removal of Maleyl Groups	100
4.8.3.4	Separation of Acid-Soluble Maleyl-Tryptic Peptides	102
4.8.3.5	Separation of Acid-Insoluble Maleyl-Tryptic Peptides	102
4.9	Sequencing of Peptides	103
4.10	FAB Mass Spectrometry	103
4.11	Separation of Phosphofructokinase Isozymes Using Non-Dissociating Conditions	103
4.12	Separation of Phosphofructokinase Isozymes Using Dissociating Conditions	105
CHAPTER 5	RESULTS	106
	CHARACTERIZATION OF SHEEP LIVER PHOSPHOFRUCTOKINASE	
5.1	SDS-PAGE of Purified Sheep Liver Phosphofructokinase	106
5.1.1	Molecular Weight Determinations of Sheep Heart and Liver PFK	106
5.2	Separation of Phosphofructokinase Isozymes	112
5.2.1	Separation of PFK Isozymes Using Non-Dissociating Conditions	113
5.2.2	Separation of PFK Isozymes Using Dissociating Conditions	118

5.3	Amino Acid Compositions of Sheep Heart and Liver Phosphofructokinase	118
5.4	Peptide Mapping of CNBr Peptides of Muscle and Liver PFK on FPLC	121
5.5	Peptide Mapping of Tryptic Digests of Muscle and Liver PFK on HPLC	124
5.6	Peptide Mapping of Ammonium Bicarbonate-Insoluble Tryptic Peptides on HPLC	127
5.7	Peptide Mapping of CNBr Peptides of Muscle and Liver PFK on HPLC	127
CHAPTER 6	RESULTS	132
	AMINO ACID SEQUENCE OF SHEEP LIVER PHOSPHOFRUCTOKINASE	
6.1	CNBr Peptides	132
6.1.1	Separation and Amino Acid Sequence of the Low Molecular Weight CNBr Peptides	134
6.1.2	Separation and Amino Acid Sequence of the High Molecular Weight CNBr Peptides	141
6.2	Tryptic Peptides	157
6.3	Maleyl-Tryptic Peptides	166
CHAPTER 7	DISCUSSION	195
7.1	General Discussion	195
7.2	Sequence and Structural Homology With Bacterial Phosphofructokinase	199
7.3	Sequence Homology Between Mammalian Phosphofructokinases	208
7.4	Comparison of the Subunit Interaction and Binding Sites	215
7.4.1	Comparison of the Residues Involved in Subunit Interactions	215
7.4.2	The Calmodulin Binding Sites	215
7.4.3	The Phosphorylation Site	217
7.4.4	The Active Site	219
7.4.4.1	The ATP Binding Site	219
7.4.4.2	Fructose 6-Phosphate Binding Site	222
7.4.5	The Fructose Bisphosphate Site	222

7.4.6	The ADP Binding Site	226
7.4.7	The Citrate Binding Site	231
7.4.8	The ATP Inhibitory Site	231
7.4.9	The Hinge	233
7.5	General Summary	235
APPENDIX		237
BIBLIOGRAPHY		238

LIST OF FIGURES

Figure		Page
1	Biosynthesis and degradation of fructose 2,6-bisphosphate in the liver.	27
2	Hypothesis of Calmodulin action in living muscle.	39
3	The effect of fructose 2,6-bisphosphate on the heat stabilization of sheep liver PFK.	71
4	Effect of a second heat step on the purification of sheep liver PFK.	73
5	Precipitation of sheep liver PFK by ammonium sulphate	75
6	Precipitation of PFK activity and protein by PEG.	78
7	Flow diagram of the purification procedure for sheep liver PFK.	81
8	The Phosphofructokinase enzyme assay.	82
9	Elution profile of sheep liver PFK from DEAE-cellulose.	84
10	Elution profile of sheep liver PFK from Cibacron Blue.	86
11	Flow diagram of the purification procedure for sheep heart muscle PFK.	92
12	Flow diagram of the preparation of the CNBr peptides for sequencing.	99
13	Flow diagram of the preparation of the tryptic peptides for sequencing.	101
14	Flow diagram of the preparation of the maleyl-tryptic peptides for sequencing.	104

15	SDS-7.5% polyacrylamide gel showing purified sheep liver PFK.	107
16	Electrophoretic mobilities of standard proteins calculated for the SDS-7.5% polyacrylamide gel shown in Fig. 15.	108
17	SDS-7.5% polyacrylamide gel of purified sheep liver PFK which had undergone proteolytic cleavage during purification.	110
18	Electrophoretic mobilities of standard proteins calculated for the SDS-7.5% polyacrylamide gel shown in Fig. 17.	111
19	Separation of sheep heart PFK on DEAE-cellulose using non-dissociating conditions.	114
20	Separation of sheep liver PFK on DEAE-cellulose using non-dissociating conditions.	115
21	SDS-7.5% Polyacrylamide gel of sheep liver PFK fractions separated on a DEAE-cellulose column using non-dissociating conditions.	117
22	FPLC peptide map of a CNBr digest of sheep heart PFK.	122
23	FPLC peptide map of a CNBr digest of sheep liver PFK.	123
24	HPLC peptide map of the ammonium bicarbonate-soluble peptides from a tryptic digest of sheep heart PFK.	125
25	HPLC peptide map of the ammonium bicarbonate-soluble peptides from a tryptic digest of sheep liver PFK.	126
26	HPLC peptide map of the ammonium bicarbonate-insoluble peptides from a tryptic digest of sheep heart PFK.	128
27	HPLC peptide map of the ammonium bicarbonate-insoluble peptides from a tryptic digest of sheep liver PFK.	129

28	HPLC peptide map of a CNBr digest of sheep heart PFK.	130
29	HPLC peptide map of a CNBr digest of sheep liver PFK.	131
30	FPLC elution profile of a CNBr digest of sheep liver PFK	133
31	HPLC elution profile of fraction CNBr G chromatographed on a Resolve RC C-18 column.	135
32	HPLC elution profile of fraction CNBr H chromatographed on a Resolve RC C-18 column.	137
33	HPLC elution profile of fraction CNBr I chromatographed on a Resolve RC C-18 column.	140
34	HPLC elution profile of fraction CNBr B chromatographed on a Vydac C-4 column.	142
35	HPLC elution profile of fraction CNBr C chromatographed on a Vydac C-4 column.	144
36	HPLC elution profile of fraction CNBr D chromatographed on a Vydac C-4 column.	145
37	HPLC elution profile of fraction CNBr E chromatographed on a Vydac C-4 column.	147
38	HPLC elution profile of fraction CNBr F chromatographed on a Vydac C-4 column.	149
39	Sequence obtained from CNBr peptides.	152
40	HPLC elution profile of a tryptic digest of sheep liver PFK	158
41	Sequence obtained from tryptic peptides	167
42	HPLC elution profile of the acid-soluble maleyl-tryptic peptides chromatographed on a Mono-Q ion-exchange column.	170

43	HPLC elution profile of fraction MS 1 chromatographed on a Vydac C-18 column.	171
44	HPLC elution profile of fraction MS 2 chromatographed on a Vydac C-18 column.	176
45	HPLC elution profile of fraction MS 3 chromatographed on a Vydac C-18 column.	179
46	HPLC elution profile of fraction MS 4 chromatographed on a Vydac C-18 column.	180
47	HPLC elution profile of fraction MS 5 chromatographed on a Vydac C-18 column.	182
48	HPLC elution profile of the acid-insoluble maleyl-tryptic peptides chromatographed on a Mono-Q ion-exchange column.	184
49	HPLC elution profile of fraction MI 1 chromatographed on a Vydac C-18 column.	185
50	HPLC elution profile of fraction MI 2 chromatographed on a Vydac C-18 column.	187
51	HPLC elution profile of fraction MI 3 chromatographed on a Vydac C-18 column.	188
52	Sequence obtained from maleyl-tryptic peptides.	190
53	Amino acid sequence of sheep liver PFK obtained from the three digestion methods used.	193
54	Amino acid sequence of sheep liver PFK.	196
55	Schematic view of two subunits in the <u>Bs</u> -PFK tetramer, viewed along the x-axis.	201

56	Computer graphic view of two subunits of <u>E. coli</u> PFK viewed along the x-axis and y-axis, from the computer program FRODO.	202
57	Schematic diagram of the proposed tertiary structure of a mammalian PFK monomer.	206
58	Schematic diagram of the proposed mammalian PFK tetramer.	207
59	Computer graphic view of the ATP binding site of <u>E. coli</u> PFK from the computer program FRODO.	221
60	Conservation of the residues at the active site of mammalian PFK as compared to the <u>Bs</u> enzyme.	224
61a	Computer graphic view of the ATP binding site of <u>E. coli</u> PFK from the computer program FRODO.	225
61b	Computer graphic view of the F6P binding site of <u>E. coli</u> PFK from the computer program FRODO.	225
62	Residues at the proposed F26BP binding site.	227
63	Conservation of the residues at the ADP effector site of mammalian PFK as compared to the <u>Bs</u> enzyme.	230
64	Schematic diagram of the postulated ATP inhibitory site of mammalian PFK.	234

LIST OF TABLES

Table		Page
I	Subunit molecular weights of the muscle, liver, and platelet isozymes of human, rat and rabbit phosphofructokinases.	9
II	K _i ATP values of rabbit muscle and liver phosphofructokinase.	14
III	Michaelis constants for F6P and ATP for rabbit muscle and liver phosphofructokinase.	15
IV	Activation of rabbit muscle and liver phosphofructokinase by adenine nucleotides.	17
V	Effect of NH ₄ ⁺ and K ⁺ on the activity of rabbit muscle and liver phosphofructokinase.	19
VI	Inhibition of rat liver phosphofructokinase by TCA cycle intermediates.	20
VII	Inhibition of rabbit muscle and liver phosphofructokinase by citrate.	20
VIII	Inhibition of rabbit muscle and liver phosphofructokinase by phosphate esters.	22
IX	Phosphate content in muscle.	30
X	Influence of metabolic state on the degree of phosphorylation of muscle PFK.	32
XI	Proposed number of metabolite binding sites in PFK.	53
XII	Homogenization buffers used for the purification of liver PFK	64

XIII	Components of the ten buffer systems used in the homogenization buffer trial.	65
XIV	Results from the homogenization buffer trial.	67
XV	Results from the homogenization experiment.	69
XVI	Ammonium sulphate fractionations used in the purification of liver PFK from different species, and the resulting PFK yields.	76
XVII	Purification of sheep liver PFK.	87
XVIII	Distribution of PFK activity in rabbit tissues.	88
XIX	Purification of liver PFK from different sources.	89
XX	Purification of sheep heart PFK.	93
XXI	Amino acid composition of sheep heart muscle and sheep liver PFK.	119
XXIIa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr G following HPLC.	135
XXIIb	Alignment of sheep liver PFK peptides from fraction CNBr G with rabbit muscle and sheep heart PFK.	136
XXIIIa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr H following HPLC.	138
XXIIIb	Alignment of sheep liver PFK peptides from fraction CNBr H with rabbit muscle and sheep heart PFK.	139
XXIVa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr I following HPLC.	140

XXVa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr B following HPLC.	142
XXVb	Alignment of sheep liver PFK peptides from fraction CNBr B with rabbit muscle and sheep heart PFK.	143
XXVIa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr C following HPLC.	144
XXVIIa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr D following HPLC.	145
XXVIIb	Alignment of sheep liver PFK peptides from fraction CNBr D with rabbit muscle and sheep heart PFK.	146
XXVIIIa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr E following HPLC.	147
XXVIIIb	Alignment of sheep liver PFK peptides from fraction CNBr E with rabbit muscle and sheep heart PFK.	148
XXIXa	Amino acid sequences of liver PFK peptides isolated from fraction CNBr F following HPLC.	150
XXIXb	Alignment of sheep liver PFK peptides from fraction CNBr F with rabbit muscle and sheep heart PFK.	151
XXX	Sheep heart muscle PFK CNBr peptides.	154
XXXI	Changes in the position of methionine residues in sheep liver PFK compared to sheep muscle PFK	156
XXXIIa	Amino acid sequences of tryptic peptides from sheep liver PFK following HPLC.	159
XXXIIb	Alignment of the tryptic peptides from sheep liver PFK with rabbit muscle and sheep heart muscle PFK sequence.	161

XXXIII	Predicted [¹⁴ C]-cysteine containing peptides from a tryptic digest of sheep heart phosphofructokinase	164
XXXIVa	Amino acid sequences of acid-soluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 1.	172
XXXIVb	Alignment of the MS 1 maleyl-tryptic peptides with rabbit muscle and sheep heart muscle PFK.	174
XXXVa	Amino acid sequences of acid-soluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 2.	177
XXXVb	Alignment of the sheep liver PFK MS 2 maleyl-tryptic peptides with rabbit muscle and sheep heart muscle PFK.	178
XXXVIa	Amino acid sequences of acid-soluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 3.	179
XXXVIIa	Amino acid sequences of acid-soluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 4.	180
XXXVIIb	Alignment of the sheep liver PFK MS 4 maleyl-tryptic peptides with rabbit muscle and sheep heart muscle PFK.	181
XXXVIIIa	Amino acid sequences of acid-soluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 5.	182
XXXVIIIb	Alignment of the sheep liver PFK MS 5 maleyl-tryptic peptides with rabbit muscle and sheep heart muscle PFK.	183
XXXIXa	Amino acid sequences of acid-insoluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 1.	186
XLa	Amino acid sequences of acid-insoluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 2.	187

XLla	Amino acid sequences of acid-insoluble maleyl-tryptic peptides from sheep liver PFK isolated from fraction 3.	188
XLlb	Alignment of the sheep liver PFK MI 3 maleyl-tryptic peptides with rabbit muscle and sheep heart muscle PFK.	189
XLII	Number of each amino acid residue sequenced compared to the amino acid composition.	198
XLIII	Location of the inserted amino acid sequences in sheep liver PFK compared to <u>B_S</u> PFK.	204
XLIV	Sequence homology between the N and C-terminal halves of mammalian PFKs compared to <u>B_S</u> PFK.	209
XLV	Sequence homology between mammalian PFKs.	209
XLVI	Types of amino acid changes.	211
XLVII	Most frequently observed amino acid replacements between muscle PFKs and sheep liver PFK.	212
XLVIII	Residue changes involving major charge changes between sheep liver and muscle PFKs.	214
XLIX	Percentage of amino acid changes resulting from single and double base changes	214
L	Conservation of residues involved in subunit interactions compared to the <u>B_S</u> enzyme.	216
LI	Residues involved with the binding of ATP.	220
LII	Residues involved with the binding of fructose 6-phosphate.	223
LIII	Residues involved with the binding of ADP.	228